Molecular ablation of ventricular tachycardia after myocardial infarction. - Wikidata - wikimedia - TriplyDB

Molecular ablation of ventricular tachycardia after myocardial infarction.

Molecular ablation of ventricular tachycardia after myocardial infarction.

http://www.wikidata.org/entity/Q35613114

about

Gene delivery technologies for cardiac applications Gene and cell therapies for the failing heart to prevent sudden arrhythmic death Allogeneic cardiospheres delivered via percutaneous transendocardial injection increase viable myocardium, decrease scar size, and attenuate cardiac dilatation in porcine ischemic cardiomyopathy Making better scar: Emerging approaches for modifying mechanical and electrical properties following infarction and ablation Three-dimensional whole-heart T2 mapping at 3T.Mechano-signaling in heart failure Magnetic resonance-based anatomical analysis of scar-related ventricular tachycardia: implications for catheter ablation.Gene therapies for arrhythmias in heart failure.Selective molecular potassium channel blockade prevents atrial fibrillation Regenerative therapies in electrophysiology and pacing.Susceptibility to arrhythmia in the infarcted heart depends on myofibroblast density.Assessment of distribution and evolution of mechanical dyssynchrony in a porcine model of myocardial infarction by cardiovascular magnetic resonance.Targeted high-efficiency, homogeneous myocardial gene transfer.Cell and gene therapy for arrhythmias: Repair of cardiac conduction damage SkM1 and Cx32 improve conduction in canine myocardial infarcts yet only SkM1 is antiarrhythmic Effect of skeletal muscle Na(+) channel delivered via a cell platform on cardiac conduction and arrhythmia induction.Gene therapy approaches to ventricular tachyarrhythmias.A swine model of infarct-related reentrant ventricular tachycardia: Electroanatomic, magnetic resonance, and histopathological characterization.Connexin43 gene transfer reduces ventricular tachycardia susceptibility after myocardial infarction.Gene therapy for ventricular tachyarrhythmias.Gene therapy for cardiac arrhythmias: a dream soon to come true?Stem cells in the heart: what's the buzz all about?--Part 1: preclinical considerations Recognition of Fibrotic Infarct Density by the Pattern of Local Systolic-Diastolic Myocardial Electrical Impedance.Ventricular tachycardia from the healed myocardial infarction scar: validation of an animal model and utility of gene therapy Gene therapy to treat cardiovascular disease.Molecular mechanisms of inherited arrhythmias.Modification of cardiovascular ion channels by gene therapy.Gene therapy strategies for cardiac electrical dysfunction.Regenerative therapies in electrophysiology and pacing: introducing the next steps.Cardiac electrical remodeling in health and disease.Cardiac gene therapy in large animals: bridge from bench to bedside.Stem cell therapy for electrophysiological disorders.Gene therapy for heart disease: molecular targets, vectors and modes of delivery to myocardium.A role for membrane shape and information processing in cardiac physiology.Gene therapy to restore electrophysiological function in heart failure.Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation.Massive Accumulation of Myofibroblasts in the Critical Isthmus Is Associated With Ventricular Tachycardia Inducibility in Post-Infarct Swine Heart.Can heart function lost to disease be regenerated by therapeutic targeting of cardiac scar tissue?Gene Therapy for Post-infarction Ventricular Tachycardia.GENE AND CELL THERAPY FOR LIFE-THREATENING CARDIAC ARRHYTHMIAS.

P2860

Q26863362-FA8E8AB6-B3C8-4546-A658-622BB9351C88 Q26865425-59D03B7C-819E-45A7-9DEF-53F88C37429A Q27322954-A389132F-1499-4906-95CC-375A6883DC64 Q30277999-13504118-530F-42A9-8C0F-818F8142F69A Q30854192-66648CB4-F419-4440-B54A-B51EEA15DD78 Q33663368-B3DA56BD-E37A-4DCB-B3BD-97C29F2E262D Q33743749-DBEB88C9-24D7-4006-9BAD-0C68EC3623A9 Q33804951-EE6016DB-6A94-4EBC-BD3B-5CD317EE64B1 Q33943789-9BC812BB-30A3-498E-83DE-D707762B9496 Q35163143-659DF8BF-82F5-4E57-BFDC-574CC2C4E8F1 Q35224007-B046C1F6-7AB8-47B0-8AEE-5EE54B8FF6A7 Q35707537-1DC6971B-35FB-4F79-BC3C-C33C5FFDC892 Q35990749-3BDA6112-457C-49F4-8518-8E2D53751969 Q36077259-67AFE8C1-F5E4-4199-A3A0-EBDB9E24B168 Q36135223-2C22459A-527B-4101-B595-3B23D41F30C0 Q36189106-FA5C2F42-9CDA-4708-B9DC-1823C5FAFDB5 Q36238863-D541BDB9-F959-4A3E-A76D-BC06917A065E Q36561438-5C32B590-423A-4171-ABDB-194CEB0FBC61 Q36627790-1754E638-0A20-4D79-A5C2-F98EA0583B4F Q36726175-6D59877E-76EF-4AF5-B362-DF37B28DB610 Q36800517-C41351AB-CBBE-44EB-98AE-DF4FE8D2B2BD Q37153062-111EFED7-B95A-428F-BD09-E7325F928758 Q37221231-23019960-7D1B-442B-BFEA-64A22C247829 Q37309270-70769143-785A-4473-9302-B0C0868C0187 Q37310450-DB25FCD2-5866-4FB5-B348-08F922A65A7C Q37480777-114B93C3-D969-4453-9597-E272FF6F09B2 Q37578556-7EF16A50-1D1D-48A3-985F-F7530A663758 Q37778878-487351E7-1EBE-4D1B-9948-13DA426379C3 Q37821376-F53E7330-822D-4DA2-9FD2-BDB90C171AE2 Q37840780-2C464DB2-1024-42AB-8768-FBFC0F5F74E6 Q37981008-5BB35129-8A4B-4D93-8891-EE5B9258EF4E Q38129803-8E8D7EBF-651D-43DF-B444-9D5A83F46B45 Q38132253-446E9240-2E6E-45A1-A758-FD97435018A2 Q38240412-92882B2A-FEDA-45DF-870A-10F00C11B92F Q38416938-F9A966C5-2A53-4231-A583-908032F32C76 Q38435600-295CC733-D0EF-4B5F-A3D8-7728DDA7518A Q38645319-EC68969D-174C-4AA9-BCEA-66918BC0A5EA Q38846401-FCD7745B-1A8B-451B-9A99-069F87576B9A Q39137447-A3343C87-C424-4A00-83E3-6F48E2D15ABF Q39282470-C94EC397-6A18-4ABB-90E9-AB78E957483B

P2860

Molecular ablation of ventricular tachycardia after myocardial infarction.

http://www.wikidata.org/entity/Q35613114

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Molecular ablation of ventricular tachycardia after myocardial infarction.

@ast

Molecular ablation of ventricular tachycardia after myocardial infarction.

@en

type

label

Molecular ablation of ventricular tachycardia after myocardial infarction.

@ast

Molecular ablation of ventricular tachycardia after myocardial infarction.

@en

prefLabel

Molecular ablation of ventricular tachycardia after myocardial infarction.

@ast

Molecular ablation of ventricular tachycardia after myocardial infarction.

@en

P1433

Q35613114-51CEB5BC-2585-4CC1-A2FE-44DFBE0DC7D0

P1476

Q35613114-9FBE7C0F-9F4D-4F97-949A-61C73F04BD49

P2093

Q35613114-4F482ED1-2FDD-4142-AC90-9E1485440640

Q35613114-CA65973B-6E19-4140-A936-B23ECD983460

Q35613114-E149E447-ED10-4226-93C6-E10A13A5CC1E

Q35613114-F4D47907-35C5-4122-95DD-157EC697D060

P2860

Q35613114-1879807A-AC51-4D9A-AE66-E014CF4F07E2

Q35613114-18999D11-EBCF-4CEA-B403-549A117F5991

Q35613114-2EC0C7B9-ECCF-46B3-AA5C-6580927AA548

Q35613114-4C8A6CDB-1579-4F5D-A610-C0BC6D8C0000

Q35613114-6EE86B77-2191-4D61-9F05-F1C9F10BC45F

Q35613114-719B8076-12D2-40E9-A3AD-75D15AC20848

Q35613114-B9A561D6-A337-4364-9B34-B4CFAAF5A544

Q35613114-BB902C7A-2F93-453A-8AE0-D69E94E83315

Q35613114-D7600D1D-C6D8-4178-B1C9-9063916D64FB

Q35613114-EA3D6A93-C7FB-4B44-9A24-0940F376FB38

P2888

Q35613114-1946E0F9-508C-4334-83DE-0BED51C952F2

P304

Q35613114-08FFC71D-BB45-4481-B850-801A65114473

P31

Q35613114-6C3B3368-24BE-4801-B0BB-30A2A2F82F87

P356

Q35613114-77FBEF77-528C-459A-9280-1CEC02C2350A

P407

Q35613114-196FF56C-B9DA-4DF1-A6FE-C2A6CBCEA3E2

P433

Q35613114-33159703-4001-4D7E-85C2-998868919FD5

P478

Q35613114-C56A9782-7548-4403-A86B-25802C25D073

P577

Q35613114-A6887D31-E90B-4ABF-85BF-F34CD96BCE04

P5875

Q35613114-E11A25CB-42E2-4D27-BE8C-0F06314EDE9C

P698

Q35613114-BFC7CB13-C033-4389-90E8-60B007F11E1D

P921

Q35613114-8A221E57-2E0A-4291-B7E4-F391B9BB5DFD

P932

Q35613114-7EA293A6-235D-42F7-BC85-E71AE0B1EBF9

P356

P1433

Nature Medicine

P1476

Molecular ablation of ventricular tachycardia after myocardial infarction.

@en

P2093

Amy D McDonald

http://www.w3.org/2001/XMLSchema#string

J Kevin Donahue

http://www.w3.org/2001/XMLSchema#string

Kan Kikuchi

http://www.w3.org/2001/XMLSchema#string

Tetsuo Sasano

http://www.w3.org/2001/XMLSchema#string

P2860

Biological pacemaker created by gene transfer.

Spectrum of HERG K+-channel dysfunction in an inherited cardiac arrhythmia.

Avoidance of immune response prolongs expression of genes delivered to the adult rat myocardium by replication-defective adenovirus.

Cellular uncoupling can unmask dispersion of action potential duration in ventricular myocardium. A computer modeling study.

Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors.

Expression and function of a biological pacemaker in canine heart.

In vivo gene transfer of Kv1.5 normalizes action potential duration and shortens QT interval in mice with long QT phenotype.

Focal modification of electrical conduction in the heart by viral gene transfer.

Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors.

Pacemaker and ICD generator malfunctions: analysis of Food and Drug Administration annual reports.

P2888

P304

1256-1258

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM1503

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2006-10-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6724670

http://www.w3.org/2001/XMLSchema#string

P698

17072309

http://www.w3.org/2001/XMLSchema#string

P921

P932

1783685

http://www.w3.org/2001/XMLSchema#string